News

Naruto Was Never Really a Kids’ Show (And I’ll Tell You Why)
While shonen anime and manga have treaded darker territory since the days of Naruto, it begs the question of whether it deserves the "kids show" label.
BMJ7d
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Objective To evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumour activity of AMG 404, a fully human IgG1 monoclonal antibody targeting programmed cell death-1, in ...
archive8d
Early Mormon Documents, Volume 1
remove-circle Internet Archive's in-browser bookreader "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see ...
DSIJ Pvt Ltd15d
Penny Stock Below Re 1 Hit 20 Per Cent Upper Circuit With Heavy Volume After Reporting Turnaround Net Profit
The stock’s 52-week high is Rs 1.82 per share and its 52-week low is Re 0.59 per share. The shares of the company saw a spurt in volume by more than 7 times on the BSE. DSIJ's ‘Penny Pick’ service ...
archive21d
2016 Australia Building Code, Volume 1
Ask the publishers to restore access to 500,000+ books. The Internet Archive keeps the record straight by preserving government websites, news publications, historical documents, and more. If you find ...
The Lancet21d
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label ...
aState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China bState Key ...
BMJ23d
Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia ...
Introduction Enterococcus spp is responsible for 8%–15% of total bacteraemias with an associated global mortality around 23%–30%. Regarding the clinical ...
The Lancet25d
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults
aVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA bHIV-Specific Immunity Section, Laboratory of Immunoregulation, ...